CORMORANT ASSET MANAGEMENT, LP purchased 4.4% of their position (2.60M shares) of AMBRX BIOPHARMA CAYMAN, INC. on the open market
Open‑market purchase worth $25.32M — a small addition. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 4/17/2023ACC: 0000929638-23-001185
10% Owner
Since Mar 2023
+2.60M
Net shares
Net buyer
$25.32M
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
2.60M acquired
Non-Derivative Transactions3
Ordinary Shares
Indirect
Shares
+1.19M
Price / share
$9.16
Trade value
$10.94M
% of position
2.0%
4/13/2023
59.50M→60.69M
Ordinary Shares
Indirect
Shares
+841.97K
Price / share
$9.96
Trade value
$8.38M
% of position
1.4%
4/14/2023
60.69M→61.54M
Ordinary Shares
Indirect
Shares
+562.12K
Price / share
$10.67
Trade value
$6M
% of position
0.9%
4/17/2023
61.54M→62.10M
Total
Net shares
+2.60M
Net value
$25.32M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Indirect | 4/13/2023 | P · Purchase | +1.19M | $9.16 | $10.94M | 2.0% | 59.50M | 60.69M |
| Ordinary Shares Indirect | 4/14/2023 | P · Purchase | +841.97K | $9.96 | $8.38M | 1.4% | 60.69M | 61.54M |
| Ordinary Shares Indirect | 4/17/2023 | P · Purchase | +562.12K | $10.67 | $6M | 0.9% | 61.54M | 62.10M |
| Total | +2.60M | $25.32M | ||||||
Derivative Transactions0
No derivative transactions reported